Shire Plc became a hot property in health care by buying promising drugs, not developing them in- house. That may help AbbVie Inc. avoid the political hurdles that hurt Pfizer Inc.’s bid for AstraZeneca Plc.
When Pascal Soriot took the helm at AstraZeneca Plc in 2012, he inherited a company with a looming patent cliff and an ailing pipeline after a string of drug development setbacks.
Novartis AG’s troubled acquisition of Chiron Corp.’s vaccine business has one last hope -- approval of a shot to protect against a meningitis-causing bacteria.
Actelion Ltd. Chief Executive Officer Jean-Paul Clozel has staked the future of the company he founded on an experimental drug that analysts say has a 63 percent chance of success.
With drugmakers pursuing deals like never before, Shire Plc’s best defense against becoming a target may be to go on the hunt itself.
Novartis AG plans to seek approval of a medicine for chronic heart failure sooner than expected, advancing its effort to build a portfolio of cardiac therapies.